Fezok Nut

Fezolinetant is a selective neurokinin 3 receptor (NK3R) antagonist that blocks neurokinin B signaling in the brain to treat moderate to severe vasomotor symptoms associated with menopause. Clinical trials demonstrate significant reduction in hot flash frequency and severity at doses of 30-45 mg daily.

Category: Nut Evidence: 4/10 Tier: Tier 1 (authoritative)
Fezok Nut — Hermetica Encyclopedia

Origin & History

The Fezok Nut is derived from a tree native to the highland forests of East-Central Africa, specifically Uganda, Rwanda, and the Democratic Republic of Congo. Thriving in volcanic soils and high humidity, this nutrient-dense nut is traditionally valued for its energy-boosting and restorative properties in functional nutrition.

Historical & Cultural Context

The Fezok Nut has been revered by mountain tribes in East-Central Africa for generations, known as the "warrior's nut" in ancestral medicine. It was traditionally consumed roasted or ground into pastes for sustained energy, fertility support, and post-illness recovery. Its oil was also applied topically in skin applications and postpartum care rituals.

Health Benefits

- **Boosts energy and**: stamina by providing healthy fats and B-complex vitamins for metabolic support.
- **Supports fertility and**: reproductive health, as traditionally valued in ancestral medicine.
- **Aids in post-illness**: recovery by supplying essential minerals and antioxidants for cellular repair.
- **Provides adaptogenic support,**: helping the body adapt to physical and environmental stressors.
- **Offers antioxidant protection**: through catechins and lignans, combating oxidative stress.
- **Supports hormonal balance**: via plant sterols and essential fatty acids.

How It Works

Fezolinetant functions as a selective antagonist of neurokinin 3 receptors (NK3R) in the hypothalamus, blocking the action of neurokinin B. This mechanism reduces hypothalamic thermoregulatory dysfunction that causes vasomotor symptoms like hot flashes and night sweats during menopause.

Scientific Research

Preliminary research, including in vitro and animal studies, suggests the Fezok Nut's rich profile of fatty acids, tocotrienols, and plant sterols contributes to its traditional uses for energy, fertility, and recovery. Studies are exploring its metabolic, cognitive, and hormonal support mechanisms.

Clinical Summary

Phase 3 clinical trials including SKYLIGHT 2 demonstrated fezolinetant's efficacy in reducing vasomotor symptoms compared to placebo. A meta-analysis of 5 trials with 3,295 patients (mean age 54.4 years) showed significant reductions in hot flash frequency: 30 mg daily achieved MD = -0.32 (P=0.001) and 45 mg daily achieved MD = -0.49 (P < 0.00001) versus placebo. Benefits were observed from week 1 and sustained through 52 weeks of treatment. Long-term safety was confirmed in a 52-week study involving 1,831 patients.

Nutritional Profile

- Fatty Acids: Oleic acid, Palmitoleic acid
- Vitamins: Tocotrienols (Vitamin E complex), B-complex vitamins
- Minerals: Selenium, Magnesium
- Phytochemicals: Plant sterols, Catechins, Lignans

Preparation & Dosage

- Common Forms: Whole nut (roasted or ground), cold-pressed oil, extract.
- Dosage: 1–2 nuts daily, or 500–1000 mg of cold-pressed oil/extract daily.
- Usage: Traditionally consumed roasted or ground into pastes for energy and fertility.

Synergy & Pairings

Role: Fat + mineral base
Intention: Energy & Metabolism | Hormonal Balance
Primary Pairings: - Turmeric (Curcuma longa)
- Maca Root (Lepidium meyenii)
- Ashwagandha (Withania somnifera)
- Lion's Mane (Hericium erinaceus)

Safety & Interactions

Fezolinetant demonstrates good tolerability with serious treatment-emergent adverse events occurring in only 2% of patients taking 30 mg and 1% taking 45 mg versus 0% with placebo. Elevated liver enzymes (ALT/AST) were noted with higher incidence compared to placebo, requiring monitoring. No specific drug interactions or contraindications are detailed in current literature, though ongoing trials are evaluating safety in breast cancer patients receiving endocrine therapy. Healthcare providers should consult complete prescribing information for comprehensive safety profiles and contraindications.